Aug 31, 2026 | Diabetes, GLP-1s, Weight loss, Weight loss drugs, Weight management
GLP-1s drop weight, but with a notable side effect: Expanded employer budgets. Weight-loss drugs have led prescription drug growth over the past five years. New data show how sharply GLP-1 weight-loss drugs can increase pharmacy spending. Segal’s Health Plan Cost...
May 27, 2026 | Cancer, Claims, Client Report, GLP-1s, Heart disease, Specialty Drugs, Stop-Loss, Trend
A new Sun Life analysis shows high-cost claims continue to strain employer health plans. The annual High-Cost Claims and Injectable Drug Trends report identifies comorbid conditions, long inpatient stays, and injectable specialty drugs as primary drivers of claims...
Feb 10, 2026 | Benefits Advisory Conference, Benefits management, Cancer, Caroline Fraker, Compliance, Forensic claims review, Gene therapy, GLP-1s, High-cost claims, MedBen University, No Surprises Act (NSA), Obesity, Orphan diseases, Pharmacy, Specialty Drugs, Stop-Loss, Transplants
Consultants and advisors from 10 different states attended the MedBen 2026 Benefits Advisory Conference on January 28. The event featured insights from some of the industry’s most respected voices and gave brokers a clearer view of today’s benefits landscape, what...
Dec 15, 2025 | GLP-1s, MedBen Rx, Medicaid, Pharmacy, Private employers, Weight loss, Weight loss drugs
In recent months, a growing number of U.S. states have pulled back on covering GLP-1 medications for obesity under their Medicaid programs, even as the drugs remain broadly covered for diabetes. A recent KFF survey shows that while 16 state Medicaid programs still...
Nov 3, 2025 | GLP-1s, MedBen Rx, Obesity, Weight loss, Weight loss drugs, Weight management
A recent International Foundation of Employee Benefit Plans survey shows that while employers are open to covering GLP-1 drugs for diabetes, they’re far more hesitant to do so for weight loss. Over half of corporate and multiemployer/public plans cover GLP-1s for...
Sep 5, 2025 | Diabetes, GLP-1s, Weight loss drugs, Wellness
A recent Forbes article highlights ongoing concerns about GLP-1 weight-loss drugs: “Large-scale studies show that GLP-1s don’t lead to medical cost savings, at least not in the short term… healthcare expenditures rose, with inpatient costs accounting for the...
